Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000303
Chunk: 95

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 95
---
 alternative forum, the courts of England 
 and Wales shall, to the fullest extent permitted by law, be the sole and exclusive forum for:          |

| (A) | any derivative action or proceeding brought on behalf of the Company; |

| (B) | any action including any action commenced by a member of the Company in its own name or on behalf of the                                      
 Company, asserting a claim of breach of any fiduciary or other duty owed by any director, officer or other employee of the Company (including 
 but not limited to duties arising under the Act); or                                                                                          |

| 71 |

| (C) | an action arising out of or in connection with these Articles (pursuant to any provision of the laws of                         
 England and Wales or the Company’s memorandum of association and Articles (as either may be may be amended from time to time)), 
 or otherwise in any way relating to the constitution or conduct of the Company.                                                 |

| 146.2 | Unless the Company consents in writing to the selection of an alternative forum, the federal district                                 
 courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of 
 action arising under the United States Securities Act of 1933, as amended or any successor thereto.                                   |

| 146.3 | For the avoidance of doubt, nothing contained in this Article 146 shall apply to any action brought to                              
 enforce a duty or liability created by the United States Securities Exchange Act of 1934 Act, as amended, or any successor thereto. |

| 72 |

Exhibit 10.1

THIS HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THIS NOTE HAS BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

<div align='center'>Biodexa Pharmaceuticals PLC

Promissory Note</div>

Original Principal Amount: $600,000